• Strategic & operational responsibility was expanded to ~ 400 field & HQ associates, 8 brands and USD 3+ B franchise; leading special marketing projects for key launches, strategic and LOE brands, examples include- Identify accounts and HCP for rapid adoption across a multi brand portfolio- Designing and deploying a lean and effective operating model for Rare disease indications within Solid Tumor• Managing and leading digital transformation initiatives for field force effectiveness - Dynamic targeting and orchestration of tactics through machine learning for enhanced customer engagement - Piloting IoT based technology ecosystem for best in industry customer engagement• Govern franchise wide brand & sales planning, business development and new asset integration work-streams

• Managed multi-year brand strategy, tactical planning and senior management / IR communications • Led and managed several high impact & unique marketing & sales force programs successfully - Field force effectiveness: First franchise wide HCP attitudinal segmentation transforming the sales mindset of over 300 sales specialist, resulting in stronger franchise performance - Brand marketing programs, 2 game changing initiatives: (1) AI driven real time triggers for HCP interaction (4X conversion of leads) for KISQALI adoption, (2) CE and P2P programs to mitigate brand persistency - Brand analytics platforms, 3 critical tools: (1) HR+/HER2- patient flow market model for precise forecasting and understanding market dynamics, (2) KPI for brand performance management, (3) framework for quantifying impact of diagnostic modalities in specialized markets

• Managed multiple & simultaneous engagements with top tier pharmaceutical companies to support varied initiatives; ranging from planning & implementation of commercial strategies & tactics for new product launch or lifecycle and/or market entry to asset & portfolio valuations and designing of governance processes. • Provided thought leadership on several long term policy and vision re-framing programs associated with global antimicrobial enablement schema, value based medicine alternatives in wound care, incentivizing targeted innovation in Alzheimer’• Extensive work on R&D portfolio optimization, therapeutic area & asset prioritization. • Led and managed teams (5 – 20) on several high-intensity due diligence projects covering M&A deals for pipeline & mature assets drug and portfolio assets globally.

Operated a clean energy solutions company, building energy efficiency and captive power generation projects in NY metropolitan area.Implemented projects to save over 15MW of energy annually by converting over 3,000 businesses and multi-family buildings in NYC to LEDs and solar Expanded the strategic sales and national services delivery footprint to NYC, Long Island, DC metro, Chicago, NJ

Co-founded America’s 1st Vegan luxury lifestyle brand: GUNAS. The company has participated in over 15 national juried trade fairs, featured as best of MAGIC on ABC News. In 2015, Gunas won IN Style Magazine’s handbag designer awardOur targeted online marketing strategy since 2014, has pushed the site rank into the top 200K globally, we are signing up about 100 passionate vegan enthusiasts daily and the business has been doubling in sales volume since 2013Built a lean and efficient supply – value chain, managed entirely in-house. We now have an exclusive selection of eco-friendly materials, people loving manufacturing sites and dedicate fans across the world

Spearheaded the diligence the seed / series A investment decisions & term sheets for over dozen portfolio companies at an IP centric life sciences venture fund.

Co-founded an electronics design and manufacturing company, we built a portfolio of 50 energy efficient control components and devices for Solid State Lighting, BLDC Motors, Solar chargers and smart metersRaised the funds (equity + debt) for establishing manufacturing unit with an annual capacity of 10 million LED bulbs / 1 million smart meter board, brought in Japanese and South Korean Technology collaboratorsLed the SMT line equipment selection, negotiation & procurement, hired and built an ISO 9002 certified organization with 20 dedicated engineers and techniciansI also established a Bottom of Pyramid, energy empowerment program using products designed & manufactured in our facility. We lit up over 100 villages in India and expanded the program to Dominican Republic and Haiti by enabling grass roots partners, program continues to build momentum (over 20K lives have been impacted thus far)

- Evaluated and recommended long term antimicrobial portfolio policy for driving innovation and public health objectives globally for a top 5 pharmaceutical company- Provided valuation & recommendations on an 250MM Phase I/II first in class drug asset acquisition- Trained and mentored the entire team of consultants (10) on Decision Analysis Techniques & Tools for a Singapore based management consulting firm, SLCIn South East Asia (India, UAE), I exclusively worked with company boards and founders on building the business cases & operations of several green field projects. Three notable projects are listed below:1. Developed partnerships and rollout plan for “India One Card” a unified pan- India urban transport payment system for HBE, the leading services provider for commercial TV Channel broadcasts2. Built the business franchises plan for dialysis centers in India and Middle East for Universal Hospitals3. Led the Latin American (11 countries) Muncipal Infrastructure development program for Asia' largest waste management company (A2Z), project was put on hold after 180 days due to geo-political challenges

Specialized in providing recommendations around strategy development, portfolio management & optimization, asset valuations and decision process design to leading pharmaceutical firms. Four notable projects are listed1. Performed 3rd party valuation for a group of privately held companies and a major investment bank to secure debt financing. Also, successfully lead a team of 10 to perform consistent valuations across multiple therapeutic areas2. Developed a generic asset valuation tool and asset decision processes for one of the top 3-biotech companies including training the executives within the firm. The tool and systems are being used for prioritizing all early development projects and in-licensing opportunities3. Enabled one of the top 5 pharmaceutical companies to set long term pipeline performance goals for the entire portfolio in terms of discovery output, in – licensing activity, number of annual line extensions and NME launches4. Developed growth strategies in USA, China, Japan and emerging economies for major pharmaceutical covering several tactical challenges branded generics, new market entry, insurance policy optimization for follow on products

Led a drug delivery research and commercialization study for a novel Type – 1 Diabetes drug to hit the market since the introduction of Insulin. The eventual output was an assessment framework for evaluation of drug delivery candidates

Supported the senior management of a top 5 pharmaceutical company on developing a unified strategy and associated action plan for a combined therapeutic group, cardiovascular and metabolic diseasesDeveloped price options for an Australian Vaccine manufacturer planning to enter the US influenza vaccination space